rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Verrica Pharmaceuticals Inc.

VRCA · Nasdaq

Health CareBiotechnologyNot moving yet

VRCA stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 23 weeks. It is 37.7% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 23
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$18.4M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
42 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$17.3MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months11
Sale orders, 12 months0
Buyers · sellers5 · 0
WhoDidSharesTraded
John J. KirbyInterim CFObought5,000at $4.9318 Aug 2026filed 18 Aug 2026
Noah L. RosenbergCMObought2,030at $4.9218 Aug 2026filed 18 Aug 2026
Noah L. RosenbergCMObought4,200at $4.9117 Aug 2026filed 18 Aug 2026
Jayson RiegerCEO and Presidentbought5,000at $4.9117 Aug 2026filed 18 Aug 2026
David ZawitzChief Operating Officerbought6,000at $4.9817 Aug 2026filed 18 Aug 2026
Jayson RiegerCEO and Presidentbought20,000at $5.0614 Aug 2026filed 18 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders42+5 on the quarter
New · exited9 · 4
Reported value$28.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Caligan Partners LPunchanged · filed 14 Aug 2026923,910$5.7M00.0%
CANNELL CAPITAL LLCadded · filed 18 Aug 2026783,923$4.8M+98,800+14.4%
Affinity Asset Advisors, LLCunchanged · filed 13 Aug 2026707,338$4.3M00.0%
Velan Capital Investment Management LPunchanged · filed 14 Aug 2026471,559$2.9M00.0%
ARMISTICE CAPITAL, LLCreduced · filed 14 Aug 2026426,304$2.6M-91,877−17.7%
BOOTHBAY FUND MANAGEMENT, LLCunchanged · filed 14 Aug 2026280,734$1.7M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026279,310$1.7M+90,552+48.0%
Mariner, LLCadded · filed 13 Aug 2026207,230$1.3M+182,686+744.3%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026138,160$846K-757−0.5%
Stonepine Capital Management, LLCreduced · filed 14 Aug 202688,417$241K-11,318−11.3%
31 Mar 2023 – 30 Jun 2026
325068Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

John J. Kirby Company insiderInterim CFO · last 18 Aug 20262 · 0
Noah L. Rosenberg Company insiderCMO · last 18 Aug 20263 · 0
David Zawitz Company insiderChief Operating Officer · last 17 Aug 20262 · 0
Jayson Rieger Company insiderCEO and President · last 17 Aug 20264 · 0
Diem Nguyen Company insiderDirector · last 5 Jun 20260 · 0
Gavin Corcoran Company insiderDirector · last 5 Jun 20260 · 0
Lawrence Eichenfield Company insiderDirector · last 5 Jun 20260 · 0
Mark A. Prygocki Sr. Company insiderDirector · last 5 Jun 20260 · 0
Paul B. Manning Company insiderDirector, 10% owner · last 25 Nov 202520 · 0
Christopher G. Hayes Company insiderCHIEF LEGAL OFFICER · last 17 Mar 20253 · 8
John A. Stalfort III Company insiderDirector · last 26 Nov 20245 · 0
Gary Goldenberg Company insiderChief Medical Officer · last 27 Aug 20241 · 7

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-34.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-49.5%
Return on capital employedFY 2025 · to 31 Dec 2025-39.7%
Research spendFY 2025 · to 31 Dec 202524.9%
Share count trendFY 2025 · to 2 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$30.1M
Free cash flowFY 2025 · to 31 Dec 2025−$17.6M

Analyst forecasts

No analyst forecasts yet.